



DIL Complex, Ghodbunder Road, Thane(W)- 400 610, INDIA.

Tel. : +91-22-6798 0888

: +91-22-6798 0800

Fax : +91-22-6798 0999

Email : contact@dil.net

www.dil.net

DIL Limited

Unaudited financial results for the quarter ended June 30, 2011.

(Rupees in Lakhs)

Sr. No.	Particulars	Standalone			Consolidated		
		Unaudited Quarter ended		Audited Year Ended March 31,	Unaudited Quarter ended		Audited Year Ended March 31,
		June 30,			June 30,		
		2011 (Note 1)	2010 (Note 1)	2011 (Note 1)	2011 (Note 1)	2010 (Note 1)	2011 (Note 1)
1	a) Net Sales/ Income from Operations	397.03	340.39	1,411.77	2,282.28	1,831.68	7,677.32
	b) Other Operating Income (refer note 4)	7.58	32.73	224.99	80.64	40.77	194.75
	Net sales & other operating income	404.61	373.12	1,636.76	2,362.92	1,872.45	7,872.07
2	Expenditure	-	-	-	(41.49)	(79.22)	(255.06)
	a) (Increase)/decrease in stock-in-trade and work in process	-	-	-	770.15	475.05	2,082.53
	b) Consumption of raw-materials	-	-	-	5.39	-	5.53
	c) Purchase of traded goods	87.20	64.46	305.41	428.91	304.89	1,395.19
	d) Employees cost	29.44	28.62	116.58	135.76	98.25	415.03
	e) Depreciation/ Impairment	-	-	-	139.40	72.66	318.70
	f) Processing charges	-	-	-	-	50.16	-
	g) Exchange loss (net)	35.82	21.05	349.24	99.16	64.81	579.48
	h) Legal & professional expenses	21.68	36.75	127.36	44.88	41.94	170.62
	i) Repairs & maintenance	46.23	41.55	195.23	471.60	305.98	1,417.13
	j) Other expenditure	-	-	-	-	-	-
	Total expenditure (a to j)	220.37	192.43	1,093.82	2,053.76	1,334.52	6,129.15
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	184.24	180.69	542.94	309.16	537.93	1,742.92
4	Other income	4.20	-	30.44	12.09	1.14	41.26
5	Profit before Interest & Exceptional Items (3+4)	188.44	180.69	573.38	321.25	539.07	1,784.18
6	Interest	1.67	1.04	6.96	44.77	32.29	127.79
7	Profit after interest but before Exceptional Items (5-6)	186.77	179.65	566.42	276.48	506.78	1,656.39
8	Exceptional items	-	224.02	413.55	-	224.02	413.55
	a) Earn out income (Refer note No. 3)	-	-	1,743.59	-	-	1,564.67
	b) Profit on Sale of Investment in Subsidiary	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	186.77	403.67	2,723.56	276.48	730.80	3,634.61
10	Tax expense	38.43	99.95	546.72	64.17	164.07	834.92
11	Net profit/(loss) from Ordinary Activities after tax (9-10)	148.34	303.72	2,176.84	212.31	566.73	2,799.69
12	Provision for tax in respect of earlier years written back	-	-	-	-	-	(0.37)
13	Net Profit/(Loss) for the period (11+12)	148.34	303.72	2,176.84	212.31	566.73	2,799.32
14	Share of minority interest	-	-	-	(17.96)	(9.07)	(123.58)
15	Share of profit/(loss) in associate Companies	-	-	-	(37.97)	(34.08)	(142.89)
16	Net profit/(loss) after minority interest and share in associates	148.34	303.72	2,176.84	156.38	523.58	2,532.85
17	Paid-up equity share capital (Face value Rs 10/- per share)	229.32	229.32	229.32	229.32	229.32	229.32
18	Reserves excluding revaluation reserves	-	-	8,607.13	-	-	11,320.18
19	a) Basic and diluted EPS (Rs./Share) before extraordinary items	6.47	13.24	94.93	6.82	22.83	110.45
	b) Basic and diluted EPS (Rs./Share) after extraordinary items	6.47	13.24	94.93	6.82	22.83	110.45
20	Public shareholding	917,651	926,905	926,905	917,651	926,905	926,905
	- Number of shares	40.02%	40.42%	40.42%	40.02%	40.42%	40.42%
	- Percentage to shareholding	-	-	-	-	-	-
21	Promoters and promoter group shareholding	-	-	-	-	-	-
	a) Pledged/ Encumbered	Nil	Nil	Nil	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage to shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage to shares (as a % of the total share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
	b) Non-encumbered	1,375,547	1,366,293	1,366,293	1,375,547	1,366,293	1,366,293
	- Number of shares	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage to shareholding (as a % of the total shareholding of promoter and promoter group)	59.98%	59.58%	59.58%	59.98%	59.58%	59.58%
	- Percentage to shares (as a % of the total share capital of the Company)	-	-	-	-	-	-

@ For quarter only and not annualised except for year end results

Segment-wise Revenue, Results and Capital employed under Clause 41 of the Listing agreement

Particulars	Standalone			Consolidated		
	Unaudited Quarter ended		Audited Year Ended March 31, 2011 (Note 1)	Unaudited Quarter ended		Audited Year Ended March 31, 2011 (Note 1)
	June 30			June 30		
	2011 (Note 1)	2010 (Note 1)	2011 (Note 1)	2010 (Note 1)	2011 (Note 1)	
Segment revenue	-	-	-	1,992.35	1,537.06	6,550.65
- Bulk drugs/chemicals	305.28	314.87	1,218.14	309.78	317.87	1,230.14
- Property	99.29	58.04	265.86	99.29	58.04	265.86
- Treasury	-	-	-	-	-	-
- Entertainment	0.04	0.21	152.76	0.04	0.21	154.10
- Unallocable	-	-	-	-	-	-
Total	404.61	373.12	1,636.76	2,401.46	1,913.18	8,200.75
Less : Inter-segment revenue	-	-	-	38.54	40.73	328.68
Net sales/income from operation	404.61	373.12	1,636.76	2,362.92	1,872.45	7,872.07
Segment results {profit/(loss) before interest and tax}	-	-	-	127.93	365.98	1,397.55
- Bulk drugs/chemicals	251.08	252.42	999.32	254.70	254.65	1,008.00
- Property	97.16	56.01	71.70	97.16	56.01	250.62
- Treasury	(18.72)	(14.89)	(64.41)	(20.29)	(14.89)	(64.41)
- Entertainment	(145.28)	(112.85)	(463.67)	(146.59)	(114.46)	(468.21)
- Unallocable	184.24	180.69	542.94	312.91	547.29	2,123.55
Less: Inter-segment results	-	-	-	3.75	9.36	380.63
Less : Interest expense	1.67	1.04	6.96	44.77	32.29	127.79
Add: unallocable income	4.20	-	30.44	12.09	1.14	41.26
Exceptional items	-	224.02	413.55	-	224.02	413.55
a) Earn out income (Refer note No. 3)	-	-	1,743.59	-	-	1,564.67
b) Profit on Sale of Investment in Subsidiary	-	-	-	-	-	-
Profit before tax	186.77	403.67	2,723.56	276.48	730.80	3,634.61
Capital employed (Segment assets Less Segment liabilities)	-	-	-	6,503.77	4,686.28	6,106.76
- Bulk Drugs/chemicals	685.10	769.67	665.16	745.12	820.29	728.56
- Property	8,198.94	6,568.98	7,776.50	6,077.32	4,254.18	5,793.59
- Treasury	171.39	35.13	143.80	174.81	35.13	148.21
- Entertainment	5.37	295.02	324.98	447.33	756.79	679.70
- Unallocable	-	-	-	-	-	-
Total Capital employed	9,060.80	7,668.80	8,910.44	13,948.35	10,552.67	13,456.82

NOTES:

- DIL Limited (the Company) is in the business of renting properties, motion film production and distribution and treasury operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in manufacturing of bulk drugs, Drug discovery, development services and development of discoidal electrical motor technology and providing services of sporting and health awareness/education activities.
The above unaudited quarterly financial results are presented on a standalone basis as well as on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture.
The unaudited consolidated financial results includes the results of a subsidiary, associates and joint venture on the basis of unaudited financial statements prepared by the management.
- Based on the audited financial statements of DIL (the Company) for the year ended March 31 2011, it is possible that the criteria laid down, for the applicability of the provisions of Non-Banking Financial Company (NBFC), by The Reserve Bank of India (RBI) will be applicable to the Company. However, the Company believes that it is not pursuing any NBFC activities, and accordingly, it has made submission to the RBI for seeking clarification about the applicability of the said criteria to the Company. Based on the response from the RBI, Company will take necessary action.
- As per the terms of Share Purchase and Shareholder's Agreement (Agreements) executed by the Company on August 31, 2009 for transferring 70% of paid up equity share capital of Evotec (India) Pvt. Ltd. to Evotec AG, in addition to sales consideration of Rs. 1,117, Company was entitled to Earn out based on Earn out revenue during the twelve months period ended 31st August 2010. Accordingly during the quarter ended June 30, 2010 Company had estimated and accounted an earn out revenue of Rs. 224.02 Lakhs.
- During the previous year Company had entered into Technology Sale and Transfer agreement and transferred the bulk drug technology to FBL for a consideration of Rs. 150 Lakhs.
- During the year ended March 31, 2009, Company's subsidiary had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I.Biotech Private Limited (G.I.). Simultaneously Company has also entered into a share transfer agreement with Ronator Investments Limited (RI), a company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I in four installments to be completed by 10th February 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the earlier year Company sold 3750 shares for consideration of USD 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been extended further to 31st December 2011.
- During the current quarter, Company's subsidiary has commenced commercial production of Bulk Drugs and intermediates at its new plant set up at Dahej SEZ, Gujarat.
- The expenses of the Company in standalone results are stated net of recovery from subsidiaries.
- Previous year's/ period's figures have been regrouped wherever necessary and are not comparable
- There were no investor complaints pending at the beginning and at the end of the quarter ended June 30, 2011. 8 (eight) complaints were received and resolved during the quarter ended June 30, 2011.
- The above unaudited quarterly results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on August 10, 2011 and have been subjected to the limited review by the Statutory Auditors.

For DIL Limited


Krishna Datla
Managing Director

Thane
August 10, 2011

dil ltd.



DIL Complex, Ghodbunder Road, Thane(W)- 400 610, INDIA.

Tel. : +91-22-6798 0888

: +91-22-6798 0800

Fax : +91-22-6798 0999

Email : contact@dil.net

www.dil.net

DIL Limited

Unaudited financial results for the quarter ended June 30, 2011.

(Rupees in Lakhs)

Sr.No.	Particulars	Consolidated		
		Unaudited Quarter ended		Audited Year Ended
		June 30,		March 31,
		2011 (Note 1)	2010 (Note 1)	2011 (Note 1)
1	a) Net Sales/ Income from Operations	2,282.28	1,831.68	7,677.32
	b) Other Operating Income (refer note 4)	80.64	40.77	194.75
	Net sales & other operating income	2,362.92	1,872.45	7,872.07
2	Expenditure	(41.49)	(79.22)	(255.06)
	a) (Increase)/decrease in stock-in-trade and work in process	770.15	475.05	2,082.53
	b) Consumption of raw-materials	5.39	-	5.53
	c) Purchase of finished goods	428.91	304.89	1,395.19
	d) Employees cost	135.76	98.25	415.03
	e) Depreciation/ Impairment	139.40	72.66	318.70
	f) Processing charges	-	50.16	-
	g) Exchange loss (net)	99.16	64.81	579.48
	h) Legal & professional expenses	44.88	41.94	170.62
	i) Repairs & maintenance	471.60	305.98	1,417.13
	j) Other expenditure	2,053.76	1,334.52	6,129.15
	Total expenditure (a to j)	309.16	537.93	1,742.92
3	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	12.09	1.14	41.26
4	Other income	321.25	539.07	1,784.18
5	Profit before Interest & Exceptional Items (3+4)	44.77	32.29	127.79
6	Interest	276.48	506.78	1,656.39
7	Profit after interest but before Exceptional Items (5-6)	-	224.02	413.55
8	Exceptional items	-	-	1,564.67
	a) Earn out income (Refer note No. 3)	-	-	-
	b) Profit on Sale of Investment in Subsidiary	276.48	730.80	3,634.61
9	Profit/ (Loss) from Ordinary Activities before tax (7+8)	64.17	164.07	834.92
10	Tax expense	212.31	566.73	2,799.69
11	Net profit/ (loss) from Ordinary Activities after tax (9-10)	-	-	(0.37)
12	Provision for tax in respect of earlier years written back	212.31	566.73	2,799.32
13	Net Profit / (Loss) for the period (11+12)	(17.96)	(9.07)	(123.58)
14	Share of minority interest	(37.97)	(34.08)	(142.89)
15	Share of profit / (loss) in associate Companies	156.38	523.58	2,532.85
16	Net profit/ (loss) after minority interest and share in associates	229.32	229.32	229.32
17	Paid-up equity share capital (Face value Rs 10/- per share)			11,320.18
18	Reserves excluding revaluation reserves	6.82	22.83	110.45
19	a) Basic and diluted EPS (Rs /Share) before extraordinary items @	6.82	22.83	110.45
	b) Basic and diluted EPS (Rs./Share) after extraordinary items @	6.82	22.83	110.45
20	Public shareholding	917,651	926,905	926,905
	- Number of shares	40.02%	40.42%	40.42%
	- Percentage to shareholding			
21	Promoters and promoter group shareholding			
	a) Pledged/ Encumbered	Nil	Nil	Nil
	- Number of shares	Nil	Nil	Nil
	- Percentage to shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil
	- Percentage to shares (as a % of the total share capital of the Company)			
	b) Non-encumbered	1,375,547	1,366,293	1,366,293
	- Number of shares	100.00%	100.00%	100.00%
	- Percentage to shareholding (as a % of the total shareholding of promoter and promoter group)	59.98%	59.58%	59.58%
	- Percentage to shares (as a % of the total share capital of the Company)			

@ For quarter only and not annualised except for year end results

2

Segment-wise Revenue, Results and Capital employed under Clause 41 of the Listing agreement

Particulars	Consolidated		
	Unaudited Quarter ended		Audited Year Ended March 31, 2011
	June 30		
	2011 (Note 1)	2010 (Note 1)	(Note 1)
Segment revenue	1,992.35	1,537.06	6,550.65
- Bulk drugs/chemicals	309.78	317.87	1,230.14
- Property	99.29	58.04	265.86
- Treasury	-	-	-
- Entertainment	0.04	0.21	154.10
- Unallocable	2,401.46	1,913.18	8,200.75
Total	38.54	40.73	328.68
Less : Inter-segment revenue	2,362.92	1,872.45	7,872.07
Net sales/income from operation			
Segment results {profit/(loss) before interest and tax}	127.93	365.98	1,397.55
- Bulk drugs/chemicals	254.70	254.65	1,008.00
- Property	97.16	56.01	250.62
- Treasury	(20.29)	(14.89)	(64.41)
- Entertainment	(146.59)	(114.46)	(468.21)
- Unallocable	312.91	547.29	2,123.55
Total	3.75	9.36	380.63
Less : Inter-segment revenue	309.16	537.93	1,742.92
Less : Interest expense	44.77	32.29	127.79
Add: unallocable income	12.09	1.14	41.26
Exceptional items	-	224.02	413.55
a) Earn out income (Refer note No. 3)	-	-	1,564.67
b) Profit on Sale of Investment in Subsidiary	276.48	730.80	3,634.61
Profit before tax			
Capital employed (Segment assets Less Segment liabilities)	6,503.77	4,686.28	6,106.76
- Bulk drugs/chemicals	745.12	820.29	728.56
- Property	6,077.32	4,254.18	5,793.59
- Treasury	174.81	35.13	148.21
- Entertainment	447.33	756.79	679.70
- Unallocable	13,948.35	10,552.67	13,456.82
Total Capital employed			

NOTES:

- DIL Limited (the Company) is in the business of renting properties, motion film production and distribution and treasury operations. The Company also has strategic investments in subsidiaries, associates and joint venture which are engaged in manufacturing of bulk drugs, Drug discovery, development services and development of discoidal electrical motor technology and providing services of sporting and health awareness/education activities.
The above unaudited quarterly financial results are presented on a consolidated basis so as to include the operations of the Company's subsidiaries, associates and joint venture.
The unaudited consolidated financial results includes the results of a subsidiary, associates and joint venture on the basis of unaudited financial statements prepared by the management.
- Based on the audited financial statements of DIL (the Company) for the year ended March 31 2011, it is possible that the criteria laid down, for the applicability of the provisions of Non-Banking Financial Company (NBFC), by The Reserve Bank of India (RBI) will be applicable to the Company. However, the Company believes that it is not pursuing any NBFC activities, and accordingly, it has made submission to the RBI for seeking clarification about the applicability of the said criteria to the Company. Based on the response from the RBI, Company will take necessary action.
- As per the terms of Share Purchase and Shareholder's Agreement (Agreements) executed by the Company on August 31, 2009 for transferring 70% of paid up equity share capital of Evotec (India) Pvt. Ltd. to Evotec AG, in addition to sales consideration of Rs. 1,117, Company was entitled to Earn out based on Earn out revenue during the twelve months period ended 31st August 2010. Accordingly during the quarter ended June 30, 2010 Company had estimated and accounted an earn out revenue of Rs. 224.02 Lakhs.
- During the previous year Company had entered into Technology Sale and Transfer agreement and transferred the bulk drug technology to FBL for a consideration of Rs. 150 Lakhs.
- During the year ended March 31, 2009, Company's subsidiary had entered into an agreement for transfer of the throat lozenge business along with the trademark "Astrasept" and the related moveable assets for a consideration of Rs. 8 Lakhs, to its wholly owned subsidiary G.I.Biotech Private Limited (G.I.). Simultaneously Company has also entered into a share transfer agreement with Ronator Investments Limited (RI), a company incorporated under the legal provisions of Cyprus, to transfer its entire shareholding in G.I in four installments to be completed by 10th February 2009 for a total consideration of USD 400,000. In accordance with the share transfer agreement during the earlier year Company sold 3750 shares for consideration of USD 150,000 and recorded a profit of Rs 70.64 Lakhs. The time limit stipulated for completion of the share transfer agreement and completion of transaction has been extended further to 31st December 2011.
- During the current quarter, Company's subsidiary has commenced commercial production of Bulk Drugs and intermediates at its new plant set up at Dahaj SEZ, Gujarat.
- In accordance with clause 41, consolidated financial results have been published. However, standalone financial results are available on the Company's website www.dil.net and BSE website. For the quarter ended June 30, 2011, on a standalone basis, DIL Limited has reported Income of Rs. 408.81 Lakhs, profit before tax of Rs. 186.77 Lakhs and profit after tax of Rs. 148.34 Lakhs.
- There were no investor complaints pending at the beginning and at the end of the quarter ended June 30, 2011. 8 (eight) complaints were received and resolved during the quarter ended June 30, 2011.
- Previous year/s/ period's figures have been regrouped wherever necessary and are not comparable
- The above unaudited quarterly results have been taken on record by the Audit Committee and thereafter by the Board of Directors in its meeting held on August 10, 2011 and have been subjected to the limited review by the Statutory Auditors.

For DIL Limited


Krishna Datla
Managing Director

Thane
August 10, 2011

dil ltd.